Across TCGA pan-cancer cohorts, ANKRD20A9P Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKRD20A9P data layer compared with 21 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher ANKRD20A9P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD20A9P expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, UCEC, and PRAD are the cancer types where ANKRD20A9P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.111	0.934	<.001	42	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.030	14	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ANKRD20A9P tumor-vs-normal RNA expression · all ANKRD20A9P data types